Phathom Pharmaceuticals Hits Day Low of $12.32 Amid Price Pressure

Phathom Pharmaceuticals, Inc. experienced a notable decline today, with the stock dropping by 7.37% to touch an intraday low of USD 12.32. This performance contrasts sharply with the S&P 500, which saw a modest decline of 0.43% on the same day. Over the past week, Phathom has shown a positive trend, gaining 9.98%, but its one-month performance reflects a decrease of 11.74%. Despite the recent downturn, the company has demonstrated impressive growth over the past year, achieving a remarkable return of 118.06%, significantly outpacing the S&P 500's 17.36% return. Phathom's financial metrics reveal a complex picture. The company has a negative book value and a weak long-term fundamental strength, with net sales growing at an annual rate of 171.75% but operating profit declining at -183.29% over the last five years. Additionally, the company's debt-equity ratio stands at a low -106.02%, indicating a challenging financial position. With a market capitalization of USD 894 million, Phathom remains a small-cap player in the pharmaceuticals and biotechnology industry, attracting high institutional holdings at 100%.